SEP 14 2005 W

JCOG Rec'd PCT/PTO 14 SEP 2005

PATENT

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No: 10/539,172

Applicant(s): Bover Fuentes, et al.

Filed:

June 14, 2005

Title:

Combinations of Growth and Hormone Regulating Factors for the Treatment of

Neoplasia

TC/A.U.:

Unassigned

Examiner:

Unassigned

Docket:

976-25 PCT/US

I hereby certify this correspondence is being deposited with the United States Postal Service as first class mail, postpaid in an envelope addressed to Commissioner for Patients, PO Box 1450, Alexandria, VA 22313-1450

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In order to fulfill the requirements of candor and good faith set forth in the 37 C.F.R. §1.56, Applicant submits herewith the following Information Disclosure Statement in accordance with the provisions of 37 C.F.R. §1.97 and §1.98.

UNITED STATES PATENTS

PATENTEE	PATENT NO.	ISSUE DATE
Gandolf, et al.	5,894,018	April 13, 1999

FOREIGN PATENT DOCUMENTS

COUNTRY	PUBLICATION NO.	PUBLICATION DATE
Great Britain	GB 2 228 262 A	August 22, 1990
PCT	WO 94/10202 A	May 11, 1994
PCT	WO 98/27111 A	June 25, 1998

NON-PATENT PUBLICATIONS

1. Camby, I., et al., "Characterization of the Influence of Anti-Hormone and/or Anti-Growth Factor Neutralizing Antibodies on Cell Clone Architecture and the Growth of Human Neoplastic Astrocytic Cell Lines", *Journal of Neuro-Oncology* 1994, 20(1):67-80.

Each of the above references were listed in the International Search Report issued in the corresponding International Application. A copy of the International Search Report accompanies this IDS.

Copies of the cited references should have been provided by the International Searching Authority. Upon receipt of a Notification of Acceptance of Application indicating what items have been received by the Patent and Trademark Office, Applicant will review the same to ensure that the references were provided.

A separate listing of all the references has been set forth on the enclosed form PTO-1449. The Examiner is respectfully requested to consider these references in their entirety, and to indicate that he or she has done so by initialing the enclosed Patent and Trademark Office Form 1449.

If the Examiner has any questions relating to the present communication he or she is invited to contact Applicant's agent at the telephone number set forth below.

Applicant does not believe that any fees are due. However, if any fees are due, please charge Deposit Account No. 08-2461.

Respectfully submitted,

Edna I. Gergel, Ph.D. Registration No.: 50,819

Agent for Applicant(s)

HOFFMANN & BARON, LLP 6900 Jericho Turnpike Syosset, New York 11791 (516) 822-3550 EIG:jlw 209885_1

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE				1 .	ATTY. DOCKET NO. 976-25 PCT/US			SERIAL NO. 10/539,172		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					APPLICANT Bover Fuentes, et al.			CONFIRMATION NO. Unassigned		
(Use several sheets if necessary)				FILING DATE June 14, 2005			GROUP Unassigned			
		U.S. P	ATENT	DOCUM	ENTS	5				
EXAMINER INITIAL	DOCUMENT NUMBER	DATE		NAME		CLASS		UB ASS	FILING DATE IF APPROPRIATE	
	5,894,018	4/13/99	Gando	olf, et al.					-	
_		FOREIG	N PATE	ENT DOC	UMEI	NTS				
EXAMINER	DOCUMENT						SU		TRAN	SLATION
EXAMINER INITIAL	DOCUMENT NUMBER		N PATE	COUNTI		CLASS	SU CLA		TRAN YES	SLATION NO
		DA	ATE		RY					
	NUMBER	D/	ATE /90	COUNTI	RY					
	NUMBER GB 2228262 A	D/A 8/22	/90 /94	COUNTI	RY					

209886_1

EXAMINER

DATE CONSIDERED

Anti-Growth Factor Neutralizing Antibodies on Cell Clone Architecture and the Growth of Human Neoplastic Astrocytic Cell Lines", *Journal of Neuro*-

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

Oncology 1994, 20(1):67-80.